|
시장보고서
상품코드
1969908
AAV 수탁 개발 제조 기관(CDMO) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global AAV Contract Development And Manufacturing Organizations Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
AAV 수탁 개발 제조 기관(CDMO) 시장 규모는 2025년 9억 3,000만 달러에서 2034년에는 40억 달러에 이르고, 2026-2034년 CAGR 17.61%를 나타낼 전망입니다.
세계 AAV 위탁개발생산기관(CDMO) 시장은 아데노부수체(AAV) 벡터를 이용한 유전자치료제 수요 증가로 인해 빠르게 성장하고 있습니다. 제약회사와 바이오테크놀러지 기업들은 이러한 복잡한 제품 개발 및 제조에 있어 전문 CDMO에 의존하는 경우가 많아지고 있습니다. 희귀질환 및 유전질환을 대상으로 한 유전자치료제 후보물질 파이프라인의 확대가 AAV 생산 서비스 수요를 크게 견인하고 있습니다.
주요 성장 요인으로는 자체 제조의 높은 비용과 기술적 복잡성을 들 수 있으며, 이로 인해 기업들은 경험이 풍부한 CDMO에 아웃소싱을 추진하고 있습니다. 바이러스 벡터 생산 기술의 발전과 제조 시설의 확장도 시장 성장에 기여하고 있습니다. 유전자 치료에 대한 규제 당국의 승인 증가는 신뢰할 수 있는 제조 파트너에 대한 수요 증가를 가져왔습니다. 벤처캐피털 기업의 강력한 투자와 전략적 제휴가 시장 발전을 더욱 가속화하고 있습니다.
앞으로 더 많은 유전자 치료제가 상용화 단계에 도달함에 따라 시장은 크게 성장할 것으로 예측됩니다. CDMO 기업들은 수요 증가에 대응하기 위해 생산능력 확대와 첨단기술에 대한 투자를 진행하고 있습니다. 확장 가능한 제조 공정의 지속적인 혁신은 효율성을 향상시키고 생산 비용을 절감할 수 있습니다. 유전자 치료 산업이 성숙함에 따라 AAV CDMO 시장은 대규모 생산과 세계 유통을 지원하는 데 중요한 역할을 할 것입니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 AAV 수탁 개발 제조 기관(CDMO) 시장 : 워크플로우별
제5장 세계의 AAV 수탁 개발 제조 기관(CDMO) 시장 : 배양 유형별
제6장 세계의 AAV 수탁 개발 제조 기관(CDMO) 시장 : 용도별
제7장 세계의 AAV 수탁 개발 제조 기관(CDMO) 시장 : 최종사용자별
제8장 세계의 AAV 수탁 개발 제조 기관(CDMO) 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
LSHThe AAV Contract Development And Manufacturing Organizations Market size is expected to reach USD 4.00 Billion in 2034 from USD 0.93 Billion (2025) growing at a CAGR of 17.61% during 2026-2034.
The Global AAV Contract Development And Manufacturing Organizations (CDMO) Market is witnessing rapid growth due to the increasing demand for gene therapies that use adeno-associated virus (AAV) vectors. Pharmaceutical and biotechnology companies often rely on specialized CDMOs to develop and manufacture these complex products. The growing pipeline of gene therapy candidates targeting rare and inherited diseases is significantly driving the need for AAV production services.
Major growth drivers include the high cost and technical complexity of in-house manufacturing, which encourages companies to outsource to experienced CDMOs. Advancements in viral vector production technologies and the expansion of manufacturing facilities are also contributing to market growth. Increased regulatory approvals for gene therapies have created greater demand for reliable manufacturing partners. Strong investment from venture capital firms and strategic collaborations are further accelerating market development.
Looking forward, the market is expected to grow substantially as more gene therapies reach commercialization stages. CDMOs are expanding their production capacities and investing in advanced technologies to meet rising demand. Continuous innovation in scalable manufacturing processes will improve efficiency and reduce production costs. As the gene therapy industry matures, the AAV CDMO market will play a crucial role in supporting large-scale production and global distribution.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Workflow
- Upstream Processing
- Downstream Processing
By Culture Type
- Adherent Culture
- Suspension Culture
By Application
- Cell & Gene Therapy Development
- Vaccine Development
- Biopharmaceutical & Pharmaceutical Discovery
- Biomedical Research
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Academic & Research Institutes
COMPANIES PROFILED
- Thermo Fisher Scientific Inc, Creative Biogene, Catalent Inc, Charles River Laboratories International Inc, Danaher Aldevron, Forge Biologics, Genezen, ViroCell Biologics, Merck KGaA, Viralgen, Biovian Oy
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY WORKFLOW 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Workflow
- 4.2. Upstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Downstream Processing Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY CULTURE TYPE 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Culture Type
- 5.2. Adherent Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Suspension Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY APPLICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Application
- 6.2. Cell & Gene Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Vaccine Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. Biopharmaceutical & Pharmaceutical Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Biomedical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY END-USER 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End-user
- 7.2. Pharmaceutical & Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Workflow
- 8.2.2 By Culture Type
- 8.2.3 By Application
- 8.2.4 By End-user
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Workflow
- 8.3.2 By Culture Type
- 8.3.3 By Application
- 8.3.4 By End-user
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Workflow
- 8.4.2 By Culture Type
- 8.4.3 By Application
- 8.4.4 By End-user
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Workflow
- 8.5.2 By Culture Type
- 8.5.3 By Application
- 8.5.4 By End-user
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Workflow
- 8.6.2 By Culture Type
- 8.6.3 By Application
- 8.6.4 By End-user
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL AAV CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Thermo Fisher Scientific Inc
- 10.2.2 Creative Biogene
- 10.2.3 Catalent Inc
- 10.2.4 Charles River Laboratories International Inc
- 10.2.5 Danaher (Aldevron)
- 10.2.6 Forge Biologics
- 10.2.7 Genezen
- 10.2.8 ViroCell Biologics
- 10.2.9 Merck KGaA
- 10.2.10 Viralgen
- 10.2.11 Biovian Oy
